Novel FANCI and RAD54B Variants and the Observed Clinical Outcomes in a Hungarian Melanoma Cohort
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms26010023 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Barbara Anna Bokor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, University of Szeged, 6720 Szeged, Hungary. Hauptthemen laut MEDLINE: Melanoma, DNA Helicases, Fanconi Anemia Complementation Group Proteins, Nuclear Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hungarian Government.
Abstract (Originalsprache)
Accumulating evidence suggests that inherited melanoma is not rare and approx. one in seven individuals with melanoma has clinically relevant hereditable cancer-predisposing and/or -susceptibility variant(s). Concerning its germline genetic background, genetic screening aims to identify either variants of predisposing genes with high penetrance or variants of susceptibility genes with medium or low penetrance. However, less attention is paid to genetic testing of germline variants of genes influencing patients’ survival outcomes or enhancing the design of new therapies. We aimed to investigate whether the germline genetic background of a Hungarian melanoma cohort (n = 17) contains any pathogenic or likely pathogenic variants of the BRCA2, POLE, WRN, FANCI, PALB2, and RAD54B genes and if the presence of these variants correlate with the clinical findings of the patients, including the advanced stage of melanoma, poor prognosis, and poor survival. We identified three novel variants in the FANCI gene and one novel variant in the RAD54B gene. We detected rapid disease progression, unfavorable outcome, and therapeutic resistance in the patient carrying the likely pathogenic FANCI variant. Our study highlights the importance of screening germline variants of genes influencing melanoma progression, therapy resistance, and survival of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.
- HUN-REN-SZTE Functional Clinical Genetics Research Group, University of Szeged, 6720 Szeged, Hungary.
- Mór Kaposi Teaching Hospital, 7400 Kaposvár, Hungary.
ORCID-Profile: Flóra Kaptás, Margit Pál, Nikoletta Nagy
Förderung
- Hungarian Government
Zitieren
APA
Bokor, B. A., Abdolreza, A., Kaptás, F., Pál, M., Battyani, Z., Széll, M., & Nagy, N. (2024). Novel FANCI and RAD54B Variants and the Observed Clinical Outcomes in a Hungarian Melanoma Cohort. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26010023
Vancouver
Bokor BA, Abdolreza A, Kaptás F, Pál M, Battyani Z, Széll M, et al. Novel FANCI and RAD54B Variants and the Observed Clinical Outcomes in a Hungarian Melanoma Cohort. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms26010023
BibTeX
@article{Bokor2024,
author = {Bokor, Barbara Anna and Abdolreza, Aliasgari and Kaptás, Flóra and Pál, Margit and Battyani, Zita and Széll, Márta and Nagy, Nikoletta},
title = {Novel FANCI and RAD54B Variants and the Observed Clinical Outcomes in a Hungarian Melanoma Cohort},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms26010023}
}
EUVIMED